What is SER (SER) stock price today?

SER (SER) is currently trading at $2.10, up 1.45% today.

What is SER P/E ratio?

SER's P/E ratio is -0.96. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is SER return on equity (ROE)?

SER's return on equity (ROE) is -402.16%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is SER's market cap?

SER has a market capitalization of $22.75M.

ASE · Biotechnology

SER (SER) Stock

$2.10 +1.45% ASE: SER Healthcare

Valuation

Metric	Value
Price	$2.10
Market Cap	$22.75M
P/E Ratio	-0.96
P/B Ratio	1.30
P/S Ratio	158.33
EPS (TTM)	$-1.91
52-Week High	$7.92
52-Week Low	$1.22
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-402.16%
ROA	-77.90%
ROCE	-116.63%
Gross Margin	73.85%
Operating Margin	-188.03%
Net Margin	-163.59%
Debt/Equity	0.18
Current Ratio	1.50

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$3.0M	$1.0M	$3.0M	$0	$0
Operating Profit	$-2.0M	$-2.0M	$-3.0M	$-17.0M	$-24.0M
Net Profit	$-1.0M	$-3.0M	$5.0M	$-11.0M	$-19.0M
EPS	$-0.59	$-2.49	$0.63	$-1.51	$-1.91
Op Margin	-47.1%	-454.1%	-99.2%	-30442.9%	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$3.0M	$3.0M	$9.0M	$7.0M	$7.0M
Total Liabilities	$15.0M	$21.0M	$41.0M	$6.0M	$7.0M
Cash	$1.0M	$1.0M	$8.0M	$4.0M	$3.0M
Borrowings	$13.0M	$18.0M	$3.0M	$0	$0

Latest News

Serina Therapeutics Appoints Farrell Simon to its Board of Directors GlobeNewswire · Jul 22, 2026 Serina Says Panel Clears Dosing More Patients in Phase 1b Trial of SER-252 in Parkinson's Disease MT Newswires · Jul 9, 2026 Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease GlobeNewswire · Jul 9, 2026 Gannet BioChem and Serina Therapeutics Enter Development Partnership Supporting SER-252 Program GlobeNewswire · Jun 30, 2026 Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates GlobeNewswire · May 14, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-2.0M	$-2.0M	$-2.0M	$-17.0M	$-18.0M
Investing Cash Flow	$1.0M	$1.0M	$-1.0M	$0	$0
Financing Cash Flow	$1.0M	$0	$0	$5.0M	$0
Net Cash Flow	$0	$0	$7.0M	$-4.0M	$-1.0M
Free Cash Flow	$-2.0M	$-2.0M	$-3.0M	$-17.0M	$-18.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	0.04
FCF Yield	-88.61%
Quick Ratio	4.18
Interest Coverage	-1018.50
Return 1Y	-63.21%
Return 3Y	-92.91%
Return 5Y	-96.29%

Ownership

Insiders Held85.96%

Institutions Held9.84%

Institutions Float Held70.06%

Institutional Holder	Shares	Report Date
Sio Capital Management, LLC	1,000,000	2026-03-31
Vanguard Capital Management LLC	159,136	2026-03-31
Waverly Advisors, LLC	67,492	2026-03-31
Geode Capital Management, LLC	64,973	2026-03-31
Blackrock Inc.	58,264	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ALGS	$4.28	-1.04%	-2.29	$26.45M	0.00%
BRNSBarinthus Biotherapeutics plc	$0.67	+4.69%	-0.41	—	0.00%
CVM	$1.18	+0.00%	-0.23	$8.11M	0.00%
GNTAGenenta Science S.p.A.	$1.50	-5.66%	-3.98	$28.72M	0.00%
GRCE	$2.37	+3.04%	-2.26	$38.57M	0.00%

About SER

SER is led by CEO Steven A. Ledger, employs 12 people, headquartered in US, publicly traded since 2000.

SER stock trades at $2.10 with a market capitalization of $22.75M. The stock is valued at a price-to-earnings (P/E) ratio of -0.96, price-to-book of 1.30, price-to-sales of 158.33. Over the past 52 weeks the stock has ranged between $1.22 and $7.92, and currently trades 73.5% below its 52-week high.

On profitability, SER generates a return on equity (ROE) of -402.16%, return on capital employed of -116.63%, an operating margin of -188.03%, a net profit margin of -163.59%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks All stock screens

Run Stock Screener Investing Guides